A 52-week phase 3 clinical trial of Skyrizi, or risankizumab — a drug initially approved to treat Crohn’s disease, psoriatic arthritis and psoriasis — was shown to also achieve clinical remission in 40 percent of patients with ulcerative colitis, Abbvie announced June 15.
Read the full post on Becker's Hospital Review - Healthcare News
